Use your antibodies-online credentials, if available.
抗Human MED30 抗体:
抗Mouse (Murine) MED30 抗体:
抗Rat (Rattus) MED30 抗体:
MED30 seems to be involved in the progression of the renal cell carcinoma (RCC).
Knockdown of MED30 led to reduction of the tumour parameters proliferation, migration, and invasion in the bladder cancer (BCa) cell lines.
analysis of a novel transcript of MED30, termed MED30 short (MED30s) generated by alternative splicing
Requirement of TRAP/mediator for both activator-independent and activator-dependent transcription in conjunction with TFIID-associated TAF(II)s.
MED30 was overexpressed in gastric cancer tissues and cell lines. Moreover, MED30 overexpression increased the proliferation, migration, and invasion of gastric cancer cells
Data show a missense mutation in Med30 causing progressive cardiomyopathy in homozygous mice that, although viable during lactation, show precipitous lethality 2-3 wk after weaning.
The multiprotein TRAP/Mediator complex facilitates gene expression through a wide variety of transcriptional activators. MED30 is a component of this complex that appears to be metazoan specific (Baek et al., 2002
mediator complex subunit 30
, TRAP/Mediator complex component TRAP25
, thyroid hormone receptor associated protein 6
, mediator of RNA polymerase II transcription subunit 30
, putative mediator of RNA polymerase II transcription subunit 30
, thyroid hormone receptor-associated protein 6
, thyroid hormone receptor-associated protein complex 25 kDa component